摘要
目的评价莫西沙星在治疗肺炎支原体感染中的抗菌和抗炎作用。方法采用随机对照方法,以阿奇霉素为对照。共治疗患者36例。莫西沙星组20例,每例静脉注射400mg/d;阿奇霉素组16例,10mg(/kg·d),5～7d后改为口服,共治疗2周。结果莫西沙星组与阿奇霉素组痊愈率分别为85.0%和81.3%,有效率分别为100.0%和93.8%,病原菌清除率均为100%。不良反应发生率分别为5.0%和12.5%。莫西沙星治疗组患者治疗期间体内TNF-α和IL-6水平明显低于同期阿奇霉素治疗组。结论莫西沙星治疗肺炎支原体安全有效,并能降低体内细胞因子水平。
Objective To evaluate the antibacterial and anti-inflammatory effect of Moxifloxacin in Mycoplasma pneumoniae-infected patients. Methods Double-blind randomized study was undertaken to treat 36 patients. 20 cases were intravenous injection with Moxifloxacin （400mg/d）,and 16 cases were injected with Azithromycin as control（the oral was used after 10mg/（kg＇d） was droped in vein for 5-7 days）, totally for 3 courses. Results The curative and the effective rates of Moxifloxacin and Azithromycin were 85.0% and 81.3%, 100.0% and 93.8%, respectively. Bacterial eradication rate was 100% for each drug,the incidence of adverse reactions was 5.0% and 12.5% ,respectively. The TNF-α and IL-6 level in Moxifloxacin group was lower significantly than that of control group. Conclusion Moxifloxacin is effective and safe in the treatment of Mycoplasma pneumoniae infection,and it can decrease the cytokine level in vivo.
出处
《中国现代医生》
2008年第31期6-7,10,共3页
China Modern Doctor
